Tirzepatide contraindications: what the TikTok gets right and wrong

What did @wild_energy_95 actually say?

Honestly? It's hard to tell. The transcript is an incoherent stream of fragments about birds, Mexican people, and team support, with no meaningful medical content. The caption, written in Russian, is where the actual claims live. It lists tirzepatide contraindications, specifically mentioning people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2), and begins to mention patients with severe gastrointestinal conditions before cutting off.

So the video appears to be a Russian-language explainer about who should not use tirzepatide, but the auto-transcribed English audio is completely garbled and unrelated to the caption text. We're fact-checking the caption claims, because that's the only substance here.

Does the science back this up?

On the MTC and MEN2 contraindications: yes, the caption is accurate, and this is not a minor caveat. It is a black box warning, the FDA's most serious category.

Tirzepatide, like all GLP-1 receptor agonists, caused dose-dependent thyroid C-cell tumors in rodent studies (Eli Lilly, FDA label, 2022). Whether this translates to humans is genuinely unknown, but the mechanism is plausible. C-cells express GLP-1 receptors in rodents. The relevance to human thyroid biology is still being studied, and post-marketing surveillance is ongoing. What is not debated is the contraindication itself. Patients with a personal or family history of MTC or MEN2 type syndrome should not use tirzepatide. The FDA label says so plainly. The caption gets this right.

The truncated mention of severe gastrointestinal conditions as a contraindication is also directionally correct. Tirzepatide significantly slows gastric emptying, which creates real risks in patients with gastroparesis or severe GI motility disorders.

What did they get wrong (or right)?

The caption content, credit where it's due, is factually grounded. The MTC and MEN2 contraindications are real and important. The partial mention of GI contraindications points in the right direction.

What's wrong is context and completeness. A 160,000-view TikTok that lists contraindications without explaining why they exist is a half-measure at best. Someone watching this might think MTC is just a checkbox rather than understanding that the concern stems from animal carcinogenicity data with uncertain human applicability.

The video also omits several other significant contraindications and warnings: a history of pancreatitis, diabetic retinopathy complications in patients with type 2 diabetes, hypersensitivity reactions, and the risk of hypoglycemia when combined with insulin or sulfonylureas. Listing two contraindications and cutting off mid-sentence does not constitute responsible medical education. It creates the impression of thoroughness without delivering it.

The garbled audio transcript suggests the creator may not have been speaking coherently on camera, which raises questions about what viewers actually absorbed versus what the caption stated.

What should you actually know?

Tirzepatide's contraindication list is real and clinically meaningful. The FDA approved tirzepatide for type 2 diabetes in 2022 (Mounjaro) and for chronic weight management in 2023 (Zepbound), and both labels carry the same black box warning about thyroid C-cell tumors.

The full picture of who should avoid tirzepatide includes:

• Anyone with a personal or family history of medullary thyroid carcinoma
• Anyone with MEN2 syndrome
• Anyone with a known serious hypersensitivity to tirzepatide or its excipients
• Patients with active or history of pancreatitis require careful evaluation before use
• Patients with severe gastroparesis or other serious GI motility disorders, as tirzepatide delays gastric emptying

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 22.5% mean body weight reduction at the 15mg dose, but the same trial also documented GI adverse events as the most common reason for discontinuation. Knowing contraindications before starting is not a formality. It is the difference between a therapy working safely and causing harm.

If you are considering tirzepatide, a provider who reviews your full medical history, not a TikTok caption, is the appropriate source for this evaluation.